Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy

Javad Sharifi‐Rad, Véronique Seidel, Michalak Izabela, Margalida Monserrat-Mesquida, Antoni Sureda, Valeska Ormazábal, Felipe Andrés Zuñiga, Mangalpady Shivaprasad Shetty, Raffaele Pezzani, Alibek Ydyrys

4 more authors

Gulmira Tussupbekova, Miquel Martorell, Daniela Cornelia Călina, William Chi Shing Cho

Cell Communication and Signaling, 2023

Full text Open access: Gold Metadata (CSL-JSON)

DOI 10.1186/s12964-023-01109-0

Data confidence 85 high

How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Cancer is a leading cause of death worldwide and involves an oxidative stress mechanism. The transcription factor Nrf2 has a crucial role in cytoprotective response against oxidative stress, including cancer growth and progression and therapy resistance. For this reason, inhibitors of Nrf2 are new targets to be studied. Traditional plant-based remedies rich in phytochemicals have been used against human cancers and phenolic compounds are known for their chemopreventive properties. This comprehensive review offers an updated review of the role of phenolic compounds as anticancer agents due to their action on Nrf2 inhibition. In addition, the role of naturally-occurring bioactive anticancer agents are covered in the clinical applications of polyphenols as Nrf2 inhibitors. Video Abstract.